1. Home
  2. NAMS vs CNK Comparison

NAMS vs CNK Comparison

Compare NAMS & CNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • CNK
  • Stock Information
  • Founded
  • NAMS 2019
  • CNK 1984
  • Country
  • NAMS Netherlands
  • CNK United States
  • Employees
  • NAMS N/A
  • CNK N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • CNK Movies/Entertainment
  • Sector
  • NAMS Health Care
  • CNK Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • CNK Nasdaq
  • Market Cap
  • NAMS 3.1B
  • CNK 3.1B
  • IPO Year
  • NAMS N/A
  • CNK 2007
  • Fundamental
  • Price
  • NAMS $32.86
  • CNK N/A
  • Analyst Decision
  • NAMS Strong Buy
  • CNK Buy
  • Analyst Count
  • NAMS 9
  • CNK 11
  • Target Price
  • NAMS $41.89
  • CNK $34.91
  • AVG Volume (30 Days)
  • NAMS 974.1K
  • CNK 3.4M
  • Earning Date
  • NAMS 11-05-2025
  • CNK 10-30-2025
  • Dividend Yield
  • NAMS N/A
  • CNK 1.24%
  • EPS Growth
  • NAMS N/A
  • CNK 86.03
  • EPS
  • NAMS N/A
  • CNK 1.92
  • Revenue
  • NAMS $64,006,000.00
  • CNK $3,217,300,000.00
  • Revenue This Year
  • NAMS N/A
  • CNK $7.46
  • Revenue Next Year
  • NAMS $1.67
  • CNK $7.69
  • P/E Ratio
  • NAMS N/A
  • CNK $13.38
  • Revenue Growth
  • NAMS 762.15
  • CNK 13.80
  • 52 Week Low
  • NAMS $14.06
  • CNK $23.12
  • 52 Week High
  • NAMS $34.62
  • CNK $36.28
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 72.18
  • CNK 38.54
  • Support Level
  • NAMS $27.15
  • CNK $27.11
  • Resistance Level
  • NAMS $34.59
  • CNK $28.68
  • Average True Range (ATR)
  • NAMS 1.47
  • CNK 0.81
  • MACD
  • NAMS 0.50
  • CNK -0.25
  • Stochastic Oscillator
  • NAMS 73.37
  • CNK 0.30

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About CNK Cinemark Holdings Inc Cinemark Holdings Inc.

Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.

Share on Social Networks: